Agentix Corp. income statement AGTX

Annual Quarterly

It recorded a net loss of $485,636. Diluted earnings per share were -$0.01. Across the 4 fiscal years shown, revenue shrank from $28,375 in fiscal 2015 to $1,240 in fiscal 2022, about 64.8% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Mar 31, 2026	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Aug 31, 2021	FY 2019 Aug 31, 2019	FY 2018 Aug 31, 2018	FY 2017 Aug 31, 2017	FY 2016 Aug 31, 2016	FY 2015 Aug 31, 2015
Revenue	—	—	—	0 -100.0%	0	—	—	0 -94.8%	0 +52.0%	0
Cost of revenue	—	—	—	0 -100.0%	0	—	—	0 +0.0%	0 -33.3%	0
Gross profit	—	—	—	0 -100.0%	0	—	—	0 -97.9%	0 +58.6%	0
Research and development	0 -30.9%	0 +3.3%	0 -75.4%	1 +94.9%	0	—	—	—	0 -87.0%	0
Selling, general and administrative	0 -2.6%	0 -79.8%	0 +147.5%	0 +110.8%	0	0 -54.5%	0 -62.9%	0 +2.9%	0 -36.5%	0
Operating income	-0 +13.3%	-1 +31.1%	-1 +45.7%	-1 -2.3%	-1	-0 +9.7%	-0 +59.8%	-0 -14.2%	-0 -67.0%	-0
Pretax income	-0 +14.4%	-1 +3.1%	-1	—	-1 +0.0%	-0	—	-0	—	—
Income tax	0	0	0	0	0	—	—	—	—	—
Net income	-0 +14.4%	-1 +3.1%	-1 +57.4%	-1 -2.5%	-1	-0 +99.7%	-43 -11127.7%	-0 -28.9%	-0 -68.8%	-0
Diluted EPS	-0.01 +0.0%	-0.01	—	—	—	—	—	—	-0.05	—
Weighted average shares, basic	—	—	—	—	—	—	—	—	6	—
Weighted average shares, diluted	40 +0.0%	40	—	—	—	—	—	—	6	—
Other measures
Depreciation and amortization	—	—	—	—	—	0 -47.0%	0 +0.0%	0 +0.0%	0 +33.3%	0
EBITDA	—	—	—	—	—	-0 +9.6%	-0 +59.8%	-0 -14.2%	-0 -67.0%	-0
Interest coverage	-5.56x	-12.03x	-35.41x	—	—	-10.70x	—	-25.03x	—	—
Margins
Gross margin	—	—	—	—	54.76%	—	—	39.69%	96.85%	92.82%
Operating margin	—	—	—	—	-108,092.90%	—	—	-14,844.00%	-677.82%	-617.18%
Pretax margin	—	—	—	—	-108,092.50%	—	—	-16,937.82%	—	—
Profit margin	—	—	—	—	-108,092.50%	—	—	-16,937.82%	-685.25%	-617.18%
EBITDA margin	—	—	—	—	—	—	—	-14,832.27%	-677.21%	-616.49%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: AGTX (OTC)
Fiscal year ends: March 31
Incorporated in: NV
Headquarters: Dana Point, CA
SEC filer status: Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK: 1603345
Former names: FairWind Energy Inc. (until Jun 27, 2019)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.